Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Notes from several investment houses indicate that the insurance giant will no longer cover genetic tests for behavioral health, which includes Myriad's GeneSight, beginning Jan. 1, 2025.

Tens of thousands of clinicians have ordered the GeneSight test for almost three million patients in order to receive genetic information that is unique to each patient. The GeneSight test ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing ... pharmacogenetic tests, including Myriad’s GeneSight test, under its ...

Morningstar brands and products Company Portfolio ...